India, Oct. 26 -- Oruka Therapeutics, Inc. (ORKA) is up 11.69 percent, gaining $9.37 to $89.52 on Monday. The rise follows positive Week 16 results from the company's EVERLAST-B Phase 2b trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis. The study met its primary endpoint, with 61 percent of patients receiving the high 600 mg dose achieving complete skin clearance, or PASI 100, compared with none receiving placebo.
Oruka Therapeutics is currently trading at $89.52, up from the previous close of $80.15 after opening at $81.98 on the Nasdaq. The stock has traded between $81.98 and $91.58 during the session. Trading volume stands at about 368,000 shares, compared with an average volume of about 881,000 shares.
go...